Cargando…

GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men

The objective was to evaluate the hypothesis that growth-differentiation factor 15 (GDF-15) is an independent marker of the long-term risk for both cardiovascular disease and cancer morbidity beyond clinical and biochemical risk factors. Plasma obtained at age 71 was available from 940 subjects in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallentin, Lars, Zethelius, Björn, Berglund, Lars, Eggers, Kai M., Lind, Lars, Lindahl, Bertil, Wollert, Kai C., Siegbahn, Agneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846468/
https://www.ncbi.nlm.nih.gov/pubmed/24312445
http://dx.doi.org/10.1371/journal.pone.0078797
_version_ 1782293431958110208
author Wallentin, Lars
Zethelius, Björn
Berglund, Lars
Eggers, Kai M.
Lind, Lars
Lindahl, Bertil
Wollert, Kai C.
Siegbahn, Agneta
author_facet Wallentin, Lars
Zethelius, Björn
Berglund, Lars
Eggers, Kai M.
Lind, Lars
Lindahl, Bertil
Wollert, Kai C.
Siegbahn, Agneta
author_sort Wallentin, Lars
collection PubMed
description The objective was to evaluate the hypothesis that growth-differentiation factor 15 (GDF-15) is an independent marker of the long-term risk for both cardiovascular disease and cancer morbidity beyond clinical and biochemical risk factors. Plasma obtained at age 71 was available from 940 subjects in the Uppsala Longitudinal Study of Adult Men (ULSAM) cohort. Complete mortality and morbidity data were obtained from public registries. At baseline there were independent associations between GDF-15 and current smoking, diabetes mellitus, biomarkers of cardiac (high-sensitivity troponin-T, NT-proBNP) and renal dysfunction (cystatin-C) and inflammatory activity (C-reactive protein), and previous cardiovascular disease (CVD). During 10 years follow-up there occurred 265 and 131 deaths, 115 and 46 cardiovascular deaths, and 185 and 86 events with coronary heart disease mortality or morbidity in the respective total cohort (n=940) and non-CVD (n=561) cohort. After adjustment for conventional cardiovascular risk factors, one SD increase in log GDF-15 were, in the respective total and non-CVD populations, associated with 48% (95%CI 26 to 73%, p<0.001) and 67% (95%CI 28 to 217%, p<0.001) incremental risk of cardiovascular mortality, 48% (95%CI 33 to 67%, p<0.001) and 61% (95%CI 38 to 89%, p<0.001) of total mortality and 36% (95%CI 19 to 56%, p<0.001) and 44% (95%CI 17 to 76%, p<0.001) of coronary heart disease morbidity and mortality. The corresponding incremental increase for cancer mortality in the respective total and non-cancer disease (n=882) population was 46% (95%CI 21 to 77%, p<0.001) and 38% (95%CI 12 to 70%, p<0.001) and for cancer morbidity and mortality in patients without previous cancer disease 30% (95%CI 12 to 51%, p<0.001). In conclusion, in elderly men, GDF-15 improves prognostication of both cardiovascular, cancer mortality and morbidity beyond established risk factors and biomarkers of cardiac, renal dysfunction and inflammation.
format Online
Article
Text
id pubmed-3846468
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38464682013-12-05 GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men Wallentin, Lars Zethelius, Björn Berglund, Lars Eggers, Kai M. Lind, Lars Lindahl, Bertil Wollert, Kai C. Siegbahn, Agneta PLoS One Research Article The objective was to evaluate the hypothesis that growth-differentiation factor 15 (GDF-15) is an independent marker of the long-term risk for both cardiovascular disease and cancer morbidity beyond clinical and biochemical risk factors. Plasma obtained at age 71 was available from 940 subjects in the Uppsala Longitudinal Study of Adult Men (ULSAM) cohort. Complete mortality and morbidity data were obtained from public registries. At baseline there were independent associations between GDF-15 and current smoking, diabetes mellitus, biomarkers of cardiac (high-sensitivity troponin-T, NT-proBNP) and renal dysfunction (cystatin-C) and inflammatory activity (C-reactive protein), and previous cardiovascular disease (CVD). During 10 years follow-up there occurred 265 and 131 deaths, 115 and 46 cardiovascular deaths, and 185 and 86 events with coronary heart disease mortality or morbidity in the respective total cohort (n=940) and non-CVD (n=561) cohort. After adjustment for conventional cardiovascular risk factors, one SD increase in log GDF-15 were, in the respective total and non-CVD populations, associated with 48% (95%CI 26 to 73%, p<0.001) and 67% (95%CI 28 to 217%, p<0.001) incremental risk of cardiovascular mortality, 48% (95%CI 33 to 67%, p<0.001) and 61% (95%CI 38 to 89%, p<0.001) of total mortality and 36% (95%CI 19 to 56%, p<0.001) and 44% (95%CI 17 to 76%, p<0.001) of coronary heart disease morbidity and mortality. The corresponding incremental increase for cancer mortality in the respective total and non-cancer disease (n=882) population was 46% (95%CI 21 to 77%, p<0.001) and 38% (95%CI 12 to 70%, p<0.001) and for cancer morbidity and mortality in patients without previous cancer disease 30% (95%CI 12 to 51%, p<0.001). In conclusion, in elderly men, GDF-15 improves prognostication of both cardiovascular, cancer mortality and morbidity beyond established risk factors and biomarkers of cardiac, renal dysfunction and inflammation. Public Library of Science 2013-12-02 /pmc/articles/PMC3846468/ /pubmed/24312445 http://dx.doi.org/10.1371/journal.pone.0078797 Text en © 2013 Wallentin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wallentin, Lars
Zethelius, Björn
Berglund, Lars
Eggers, Kai M.
Lind, Lars
Lindahl, Bertil
Wollert, Kai C.
Siegbahn, Agneta
GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title_full GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title_fullStr GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title_full_unstemmed GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title_short GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
title_sort gdf-15 for prognostication of cardiovascular and cancer morbidity and mortality in men
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846468/
https://www.ncbi.nlm.nih.gov/pubmed/24312445
http://dx.doi.org/10.1371/journal.pone.0078797
work_keys_str_mv AT wallentinlars gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT zetheliusbjorn gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT berglundlars gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT eggerskaim gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT lindlars gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT lindahlbertil gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT wollertkaic gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen
AT siegbahnagneta gdf15forprognosticationofcardiovascularandcancermorbidityandmortalityinmen